Flexible Brain Interfaces Get $7.5M
Neurosoft Bioelectronics has closed an oversubscribed $7.5 million seed round to continue development of its stretchable, scalable brain-computer interface technology.
The Problem They're Solving
Current brain-computer interfaces face a fundamental materials problem: the brain is soft and dynamic, but most electrodes are rigid. This mismatch causes inflammation, signal degradation, and limits the lifespan of implanted devices.
Neurosoft's Approach
The company has developed stretchable neural electrodes that:
- Conform to brain tissue without causing damage
- Maintain signal quality over extended periods
- Can be manufactured at scale using standard semiconductor processes
- Support thousands of recording channels per device
Clinical Potential
While early applications focus on research and clinical neuroscience, the technology has implications for:
- Epilepsy monitoring — long-term, high-resolution neural recording
- Deep brain stimulation — more precise targeting with less tissue damage
- Brain-machine interfaces — higher-bandwidth communication for paralysis patients
Why It Matters
The BCI space is being held back by hardware limitations. Neurosoft's materials science breakthrough could be the enabling technology that makes next-generation brain interfaces viable for chronic clinical use — not just short-term research experiments.
